Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Non-Current Debt (2018 - 2025)

TransMedics has reported Non-Current Debt over the past 8 years, most recently at $49.6 million for Q4 2025.

  • Quarterly results put Non-Current Debt at $49.6 million for Q4 2025, down 16.48% from a year ago — trailing twelve months through Dec 2025 was $49.6 million (down 16.48% YoY), and the annual figure for FY2025 was $49.6 million, down 16.48%.
  • Non-Current Debt for Q4 2025 was $49.6 million at TransMedics, down from $54.6 million in the prior quarter.
  • Over the last five years, Non-Current Debt for TMDX hit a ceiling of $59.5 million in Q2 2025 and a floor of $34.8 million in Q1 2021.
  • Median Non-Current Debt over the past 5 years was $58.7 million (2022), compared with a mean of $51.2 million.
  • Biggest five-year swings in Non-Current Debt: skyrocketed 66.98% in 2022 and later decreased 16.48% in 2025.
  • TransMedics' Non-Current Debt stood at $35.2 million in 2021, then soared by 66.76% to $58.7 million in 2022, then grew by 0.63% to $59.1 million in 2023, then grew by 0.52% to $59.4 million in 2024, then fell by 16.48% to $49.6 million in 2025.
  • The last three reported values for Non-Current Debt were $49.6 million (Q4 2025), $54.6 million (Q3 2025), and $59.5 million (Q2 2025) per Business Quant data.